Visit "Where can I get vaccinated" or call 1-877-COVAXCO (1-877-268-2926) for vaccine information.

Colorado Medical Board
Medical Frequently Asked Questions
Information about the Medical Board including licensure, the Healthcare Professions Profile Program, and much more.
Read more about
Medical Frequently Asked Questions
0

Medical HOME

Welcome to the Medical Homepage

The Colorado Medical Board (CMB) was instituted as part of the Medical Practice Act for the purpose of regulating and controlling the practice of healing arts, which include establishing and enforcing the licensing standards for Medical Doctors (M.D.s), Doctors of Osteopathy (D.O.s), Physician Assistants (P.A.s), and Anesthesiology Assistants (A.A.s). Licensure is mandatory to practice medicine in Colorado or to treat Colorado patients. Exceptions exist for the Veterans Administration, Bureau of Indian Affairs, and Department of Defense physicians and other licensed healthcare providers.

The CMB investigates the unlicensed practice of medicine, however, it does not have authority to arbitrate or adjudicate fee disputes. The decisions made by the CMB are not subject to administrative review. The CMB is a Type I Board, meaning that it is policy autonomous and comprised of professional and public members (eight M.D.s, three D.O.s, one P.A., and four public members).

Program Information

Program/Board Members

Paula E. Martinez, Program Director

Colorado Medical Board 
1560 Broadway, Suite 1350
Denver, CO 80202

Phone: 303-894-7800  |  Fax: 303-894-7692  |  Email: dora_medicalboard@state.co.us

Donald J. Lefkowits, M.D., President & Licensing Chair
Professional Member | Term Expires: May 3, 2023

Panel A:

  • Amanda Mixon, P.A.-C, Vice President, Panel A Chair
    Professional Member | Term Expires: May 3, 2024

  • Jennifer Blair, M.D.
    Professional Member | Term Expires: May 3, 2025

  • Robert Moghim, M.D.
    Professional Member | Term Expires: May 3, 2025

  • Saughar Samali, D.O.
    Professional Member | Term Expires: May 3, 2024

  • C. Lamont Smith, Esq.
    Public Member | Term Expires: May 3, 2022

Panel B:

  • Ty T. Higuchi, Ph.D., M.D., Panel B Chair
    Professional Member | Term Expires: May 3, 2022

  • Amy E. Colen
    Public Member | Term Expires: May 3, 2023

  • Roland Flores, Jr., M.D.
    Professional Member | Term Expires: May 3, 2023

  • Keith O. Marks
    Public Member | Term Expires: May 3, 2022

  • Kian A. Modanlou, M.D.
    Professional Member | Term Expires: May 3, 2024

Licensing Panel

  • Donald J. Lefkowits, M.D., Licensing Chair
    Professional Member | Term Expires: May 3, 2023

  • Christopher A. Bates, M.D.
    Professional Member | Term Expires: May 3, 2025

  • Julie Ann Harper, P.A.-C
    Professional Member | Term Expires: May 3, 2025

  • Hien (Adam) H. Ly
    Public Member | Term Expires: May 3, 2024

  • Scott C. Strauss, D.O., FAAFP
    Professional Member | Term Expires: May 3, 2025

Public Notices

Permanent and Emergency Rulemaking Hearing - November 18, 2021

The Colorado Medical Board will hold a virtual Permanent and Emergency Rulemaking Hearing to allow stakeholders a final opportunity to provide testimony on the implementation of Colorado House Bill 20-1326 (Concerning an expansion of an individual's ability to practice an occupation in Colorado through creation of an occupational credential portability program); Colorado House Bill 21-1276 (Concerning the prevention of substance use disorders); and the subsequent proposed revisions to Rule 120 (3 CCR 713-22) to implement HB20-1326, and the proposed new rule (3 CCR 713-49) to implement HB21-1276, which will be considered for permanent and emergency adoption to comply with the legislative mandate. 

 

Stakeholder Meeting - October 25, 2021

The Colorado Medical Board will hold a virtual Stakeholder Meeting to allow stakeholders another opportunity to provide feedback on the implementation of Colorado House Bill 20-1326 (Concerning an expansion of an individual's ability to practice an occupation in Colorado through creation of an occupational credential portability program); Colorado House Bill 21-1276 (Concerning the prevention of substance use disorders); and the subsequent proposed revisions to Rule 120 (3 CCR 713-22) to implement HB20-1326, and the proposed new rule (3 CCR 713-49) to implement HB21-1276.

 

Joint Stakeholder Meeting - October 15, 2021

The State Board of Pharmacy, State Board of Nursing, Colorado Medical Board, Colorado Dental Board, Colorado Podiatry Board, State Board of Veterinary Medicine, and State Board of Optometry held a Joint Stakeholder Meeting to gather feedback to identify and create a list of prescription drugs and substances (using evidence-based practices), in addition to controlled substances, that have a substantial potential for abuse and must require pharmacists and prescription drug outlets to report those prescription drugs and substances to the Prescription Drug Monitoring Program (PDMP) when dispensed to a patient. The Board is considering the development of new rules to monitor non-controlled prescription drugs/substances, as allowed per section 12-280-404(2)(b)(I), C.R.S., of Colorado Senate Bill 21-098.

 

COLORADO MEDICAL BOARD
Notice of Stakeholder Engagement Opportunities:
Confidential Assessment and Monitoring of VoluntaryTreatment for Board Applicants and Licensees

ISSUE UNDER CONSIDERATION
The Colorado Medical Board is considering policy to clarify the parameters of
confidential assessment and monitoring of voluntary treatment for Board applicants and licenses who seek treatment through the designated peer health provider. In this vein, the Board has formed a Policy Subcommittee to consider stakeholder feedback and develop a proposed policy for Board consideration.

ENGAGEMENT OPPORTUNITIES
As the Board considers policy to clarify this important issue, we are eager to hear from our licensees, partners, and stakeholders. We engaged stakeholders early in the process to receive thoughts, opinions, and suggestions on this important issue before the Board Policy Subcommittee met on February 11, 2021, to draft a proposed policy which was presented to the Board on February 18, 2021. Stakeholders were then provided the opportunity to review and provide feedback on the Board approved proposal in mid-March 2021.

The subcommittee reconvened on March 25, 2021, to review stakeholder feedback and requested written stakeholder comment on March 30, 2021. The subcommittee met again on April 9, 23, and 30, 2021

See the April 30, 2021, proposed draft policy for stakeholder feedback and for presentation to the Board for its consideration on May 20, 2021.

We will be hosting two virtual meetings to discuss this proposed draft policy and receive feedback:

  • Wednesday, May 12, 2021, from 1:00 p.m.– 3:00 p.m.
  • Friday, May 14, 2021, from 11:00 a.m.- 1:00 p.m. 

Both meetings will follow the same virtual meeting format, so you do not need to attend twice. The meetings will be recorded and posted on the Board’s webpage and the Board members will be provided with the recordings to review the information prior to its May 20, 2021 meeting.  

If you are unable to attend a meeting, we encourage you to provide written comments to Paula Martinez, Program Director, at paula.martinez@state.co.us.

Please submit the written comments by 5:00 pm on May 14, 2021, to ensure the Board has adequate opportunity to review prior to its meeting.

Please note that all previously submitted written comments regarding this issue have been provided to the Board for review.

NEXT STEPS
The Board will meet on May 20, 2021, to consider the proposed policy and stakeholder feedback.

Prescription Drug Monitoring Program (PDMP) - Vendor Requirements
Stakeholder Town Hall Meetings

Background:

The Colorado Department of Regulatory Agencies (DORA), Division of Professions and Occupations (DPO), in conjunction with the Colorado Board of Pharmacy, is finalizing the requirements for the selection of the vendor to administer the state’s Prescription Drug Monitoring Program (PDMP) at the conclusion of the current vendor contract. These requirements will be codified and released to the public as a Request for Proposals (RFP) to begin soliciting bids for the PDMP vendor moving forward.

In support of this process, DPO staff have been conducting an ongoing market research initiative to bring transparency, engagement, and clarity to the ongoing RFP process and to reflect the Division’s effort to have a fair, transparent, and competitive process as required by the procurement code.

As part of these outreach efforts, the Division is hosting two large stakeholder town hall meetings, open to the public, to ensure that all consumers, employers, licensees, and other stakeholders have the opportunity to provide insights into the current and future function of the PDMP and inform the procurement process. The town halls will be a forum to assist the Division in gathering input from the broader community regarding best practices for prescription drug use monitoring, and any concerns the Division should be aware of and address in the procurement process.

Invitation to Participate:

On Monday, May 3, 2021, and Wednesday, May 5, 2021, DORA/DPO will be hosting virtual Stakeholder Town Hall Meetings open to all interested stakeholders, including practitioners/PDMP end-users, professional associations, and members of the wider public, to share your thoughts, observations, and concerns for consideration in the procurement process.

We hope you can join us as we continue this informative and important discussion; please send questions to: nate.c.brown@state.co.us

 

Medical Board Seeking Stakeholder Comment

The Colorado Medical Board is considering a policy to clarify the parameters of voluntary confidential treatment for Board applicants and licensees who seek treatment through the designated peer health provider. The Board towards that end has formed a Policy Subcommittee to consider stakeholder feedback and develop a proposed policy for Board consideration.

As the Board moves forward on clarifying this important issue, we are eager to hear from our licensees, partners, and stakeholders.

We engaged stakeholders early in the process to receive thoughts, opinions, and suggestions prior to the Board Policy Subcommittee meeting on February 11, 2021, which were then used to draft a proposed policy that was presented to the Board on February 18, 2021. Stakeholder meetings were subsequently held on March 10 and 15, 2021, and written comments solicited on the proposed policy.

The Policy Subcommittee currently is requesting specific stakeholder comments related to the following issues as included in the attached policy, which was provided to stakeholders prior to the March 10 and 15 meetings:

  • Define “jeopardize patient safety;”
  • Define  “patient harm;”
  • Who should determine if patient safety has been jeopardized or if a patient has been harmed?

Please provide your written feedback/comments to Paula Martinez, Program Director, at paula.martinez@state.co.us by 5 p.m. on April 5, 2021, to ensure the Board Subcommittee has adequate opportunity to review prior to its next meeting. (Please note that all previously submitted written comments regarding this issue already have been provided to the Board Subcommittee for review.)

The Board Subcommittee is scheduled to meet on April 9, 2021, to further consider stakeholder feedback and make any necessary revisions to the proposed draft policy.  The revised proposed policy will then be presented to the Board for its consideration at its May 20, 2021 meeting. 

 

Permanent Rulemaking Hearing - Rescheduled for December 18, 2020

The Colorado Medical Board has rescheduled November 19, 2020, Permanent Rulemaking Hearing for December 18, 2020. This virtual Rulemaking Hearing is for the Board to consider adopting new Rule 160, to implement Colorado Senate Bill 19-079 (Requiring Practitioners to Prescribe Controlled Substances Electronically); and Rule 170, to implement Colorado Senate Bill 20-102 (Requiring Providers to provide Disclosure of Sexual Misconduct to Patients prior to Treatment).

Legislative Updates
Meeting Minutes

Full Board Meeting Minutes

Licensing Panel Meeting Minutes

Open Embed